Weekly Digest – January 2026 Weekly Digest – January 2026 05 January 2026: Kelun-Biotech announces Breakthrough Therapy Designation granted in China for Sacituzumab Tirumotecan (sac-TMT) in combination with immunotherapy Pembrolizumab for first-Line treatment of PD-L1-positive NSCLC The Company has reached […]
Weekly Digest – January 2026 Weekly Digest – January 2026 4 January 2026: Kelun-Biotech receives Investigational New Drug Approval for ITGB6-targeted ADC SKB105 from the NMPA Kelun-Biotech has achieved a key regulatory milestone with the approval of an Investigational New […]
Weekly Digest – January 2026 Weekly Digest – January 2026 8 January 2026: Whitehawk Therapeutics advances to clinical stage with IND clearance for HWK-007 and announces IND Submission for HWK-016 Whitehawk Therapeutics received FDA clearance for its PTK7-targeted ADC HWK-007, […]
Weekly Digest – January 2026 Weekly Digest – January 2026 7 January 2026: Lonza’s Synaffix and Sidewinder Therapeutics announce multi-target License agreement to advance development of next generation Bispecific ADCs Lonza (through its subsidiary Synaffix) and Sidewinder Therapeutics entered a […]
Weekly Digest – January 2026 Weekly Digest – January 2026 7 January 2026: InduPro Therapeutics announces strategic collaboration with Lilly to develop first-in-class Bispecific/Multispecific oncology therapeutics using InduPro’s proximity-guided platform InduPro entered a global strategic collaboration, licensing agreement, and equity […]
Weekly Digest – January 2026 Weekly Digest – January 2026 6 January 2026: Convergent Therapeutics and NorthStar Medical Radioisotopes announce expanded partnership to support Convergent’s late-stage alpha-emitting radioantibody program Convergent Therapeutics and NorthStar Medical Radioisotopes expanded their partnership to co-locate […]
